Advances in Immunopeptidomics Research in Autoimmune Diseases
- MHC-I peptidome: presented on the surface of all nucleated cells, primarily derived from intracellular protein degradation products, and responsible for activating CD8⁺ T cells.
- MHC-II peptidome: predominantly presented by antigen-presenting cells (APCs), including dendritic cells, B cells, and macrophages, and responsible for activating CD4⁺ T cells.
- High-throughput HLA-I/HLA-II immunoprecipitation enrichment.
- High-sensitivity short peptide analysis based on Orbitrap platforms.
- HLA typing combined with peptide-MHC binding affinity prediction.
- Self-antigen peptide discovery and epitope annotation.
- Personalized immunopeptidome data interpretation and bioinformatics analysis.
Autoimmune diseases (AIDs) are a group of disorders in which the immune system aberrantly attacks self-tissues. Common types include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and type 1 diabetes (T1D), among others. Although dysregulated immune regulatory mechanisms have been extensively investigated, the initiating event of immune recognition, antigenic peptide fragments presented by major histocompatibility complex (MHC) molecules, collectively referred to as the immunopeptidome, remains incompletely characterized. In recent years, driven by advances in mass spectrometry technologies, immunopeptidomics has rapidly evolved into a key tool for elucidating the pathogenesis of autoimmune diseases, identifying diagnostic biomarkers, and enabling the development of personalized immunotherapies.
What Is the Immunopeptidome?
The immunopeptidome refers to the repertoire of endogenous peptides that are processed and loaded onto major histocompatibility complex (MHC) molecules and subsequently presented on the cell surface. These peptides are typically derived from intracellular protein degradation and processing and can be recognized by T cells to initiate immune responses.
Based on antigen presentation pathways, the immunopeptidome can be classified into:
In autoimmune diseases, self-antigen presentation becomes dysregulated, leading the immune system to mistakenly recognize normal tissues as foreign. Therefore, comprehensive characterization of self-antigen-derived presented peptides is essential for understanding disease mechanisms.
Research Methodologies in Immunopeptidomics
1. Isolation and Enrichment of MHC-Bound Peptides
Immunopeptidomics studies typically begin with HLA immunoprecipitation (IP), in which specific antibodies are used to enrich MHC molecules together with their bound peptides. The peptides are subsequently eluted using acid extraction and further purified via ultrafiltration or related strategies, preparing them for downstream mass spectrometric analysis.
2. High-Resolution Mass Spectrometry Identification
Commonly used platforms include Orbitrap Exploris and Fusion Lumos mass spectrometers. When coupled with data-dependent acquisition (DDA) or data-independent acquisition (DIA) strategies, these platforms enable highly sensitive detection of low-abundance MHC-bound peptides. Compared with conventional proteomics, immunopeptidomics presents unique analytical challenges due to the non-enzymatic origin, short length, low abundance, and high heterogeneity of immunopeptides, placing stringent demands on instrument performance and methodological optimization.
3. Data Analysis and HLA Restriction Prediction
By integrating HLA typing information with computational prediction tools such as NetMHCpan and MixMHCpred, peptide-MHC binding affinities can be accurately estimated, enabling discrimination of disease-specific or individual-specific peptide repertoires.
Advances in Immunopeptidomics Research in Autoimmune Diseases
1. Systemic Lupus Erythematosus (SLE)
Studies have demonstrated that the HLA-II-associated peptide repertoire in peripheral blood mononuclear cells (PBMCs) from SLE patients differs markedly from that of healthy controls. A subset of these peptides originates from ribonucleoproteins, Sm antigens, and other autoantigenic proteins. These disease-associated peptides may provide valuable insights for early diagnosis and T cell-targeted therapeutic strategies in SLE.
2. Rheumatoid Arthritis (RA)
MHC-II-presented peptides in synovial tissues of RA patients are significantly enriched in post-translationally modified peptides derived from self-proteins such as vimentin and type II collagen. Notably, citrullinated peptides have been identified as key epitopes driving RA-specific T cell responses and constitute the molecular basis for clinical anti-cyclic citrullinated peptide (anti-CCP) antibody testing.
3. Type 1 Diabetes (T1D)
During pancreatic β-cell apoptosis, a range of peptides are released, subsequently loaded onto MHC-I molecules and presented to CD8⁺ T cells. Immunopeptidomics studies have identified multiple epitopes derived from insulin, GAD65, and IA-2, which may serve as biomarkers for early screening of high-risk individuals and for the design of antigen-specific immune interventions.
Application Prospects of the Immunopeptidome
1. Biomarker Discovery for Disease Diagnosis
Compared with conventional protein abundance measurements, MHC-bound peptides exhibit higher immunological relevance and greater individual specificity. Large-scale comparative immunopeptidomic analyses enable the identification of disease-associated presented peptides, facilitating early diagnosis, prognostic evaluation, and molecular subtyping of autoimmune diseases.
2. Development of Personalized Therapeutic Targets
Epitope peptides recognized by antigen-specific T cells represent central targets for immunotherapeutic intervention. In cancer immunotherapy, neoantigen peptides have already been widely used in vaccine design and TCR-T engineering. Similarly, in autoimmune diseases, identification of pathogenic epitopes may enable precise induction of immune tolerance, offering a promising therapeutic strategy.
3. Drug Safety Prediction
Certain drug-induced adverse reactions, such as drug-induced SLE, may arise from alterations in antigen processing and presentation pathways that generate neoepitopes. Immunopeptidomics therefore serves as a valuable immunogenicity assessment tool in drug development, contributing to the mitigation of potential adverse effects.
Immunopeptidomics Services at MtoZ Biolabs
In the field of immunopeptidomics, MtoZ Biolabs leverages advanced mass spectrometry platforms and a well-established IP-MS enrichment workflow to provide a comprehensive one-stop service pipeline, including:
We are committed to delivering reliable and reproducible immunopeptidomics data to support research in autoimmune diseases, tumor immunology, and vaccine development, thereby enabling deeper insights into the fundamental mechanisms of immune recognition.
Immunopeptidomics has opened a new perspective for investigating autoimmune diseases, revealing molecular mechanisms at the level of antigen presentation and providing potential diagnostic and therapeutic targets. With continuous improvements in mass spectrometry sensitivity and computational data analysis, immunopeptidomics is steadily progressing toward clinical translation. In the future, multi-omics integration strategies incorporating single-cell sequencing, spatial omics, and artificial intelligence will further expand its application landscape. MtoZ Biolabs will continue to advance this field and support the development of precision immunology research.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
